--- title: Relay Therapeutics slug: relay-therapeutics-53082 url: /detay/relay-therapeutics-53082 type: article language: English entity: primary: Relay Therapeutics type: article categories: - name: Science And Technology slug: bilim url: /kategori/bilim - name: Engineering slug: muhendislik url: /kategori/muhendislik - name: Technology And Innovation slug: teknoloji url: /kategori/teknoloji tags: - Relay Therapeutics author: Ömer Said Aydın created_at: 2025-10-25T21:40:57.576572+03:00 updated_at: 2025-10-28T15:14:06.330812+03:00 image: https://cdn.t3pedia.org/media/uploads/2025/10/25/pJufvYDC30anQlQWmVPwGZLVuiDFJNMf.webp --- # Relay Therapeutics ## KURE Information Cards ![w0AMsv1pn7Y4h09BYdTK1Ow1uiJsR4Md.webp](https://cdn.t3pedia.org/media/uploads/2025/10/25/pPBFpjsxzllpAjd3so169LNNRgCYI90J.webp) *Relay Therapeutics* | Field | Value | |-------|-------| | Website(s) | https://www.relaytx.com | | Founded(Text) | 2016 | | Headquarters | Cambridge, Massachusetts, USA | | Team(s) | Ph.D. – Chief People Officer (organizational and talent strategy),Dr. Sara Thomas,Ph.D. – Chief Medical Officer (former Head of Translational Oncology at Merck),M.D.,Dr. David R. Kaufman,Eric Quon Tyacke – Chief Legal Officer (former senior counsel at Blueprint Medicines),Brian Adams – Chief Financial Officer (finance and operations leadership in biotech),R&D (oncology and translational research expert),Ph.D. – President,M.D.,Dr. Don Bergstrom,M.D. – President & CEO (former Chief Strategy Officer at Allergan),Dr. Sanjiv Patel | ## Article Content [Relay Therapeutics](/en/detay/relay-therapeutics-4daaf/llms.txt) is a clinical-stage precision medicine company distinguished by its motion-based drug discovery approach. Headquartered in Cambridge, Massachusetts, the company integrates molecular-level insights into protein dynamics with the drug discovery process. Its scientific framework combines [structural biology](/en/detay/biochemistry-20a86/llms.txt), biophysics, chemistry, and biology with advanced computational modeling methods. ### **Scientific Foundation and Platform Approach** [Relay Therapeutics](/en/detay/relay-therapeutics-67af7/llms.txt)’ core technology, the **Dynamo® Platform**, is based on the concept of **Motion-Based Drug Design®**. This platform aims to understand the conformational changes of proteins over time, model the functional consequences of these motions, and define how target proteins interact with potential drugs. The platform integrates **physics-based simulations, long-timescale molecular dynamics, free energy perturbation (FEP) calculations,** and **machine learning–enhanced simulation models**. The **Dynamo** process consists of three stages: 1. **Experimental characterization** of the target protein’s structural and dynamic features using techniques such as **cryo-electron microscopy (Cryo-EM)** and **room-temperature X-ray crystallography**. 2. **Hypothesis generation and virtual screening**, where potential binding pockets and modulation strategies are identified, and suitable chemical starting points are selected through **virtual screening** and **DNA-encoded library (REL-DEL)** methods. 3. **Optimization and validation**, involving molecular simulations, biophysical assays, and medicinal chemistry to refine lead compounds into development candidates. ### **Research and Clinical Programs** Relay Therapeutics develops **small-molecule therapies** for **oncology and genetic diseases**. Key programs include: - **RLY-2608**, a **mutant-selective PI3Kα inhibitor**, was evaluated in advanced breast cancer and **PIK3CA-related overgrowth spectrum (PROS)** disorders. It is currently in the global **Phase 3 ReDiscover-2** trial for **HR+, HER2-, PI3Kα-mutated breast cancer**, in combination with **fulvestrant**. - **RLY-8161**, targeting **NRAS-driven solid tumors**. - **Lirafugratinib (RLY-4008)**, an **FGFR2 inhibitor** licensed to **Elevar Therapeutics**. ### **Scientific and Technological Position** Relay Therapeutics was founded at the intersection of three major scientific advances: 1. The identification of disease-causing targets through **genomics**. 2. The visualization of **protein motion at atomic resolution** via structural biology. 3. The computational capacity to perform **molecular dynamics simulations** on biological timescales. Through the integration of these disciplines, the company develops novel therapeutic strategies targeting proteins previously considered **“undruggable.”** ### **Clinical and Ethical Approach** Relay Therapeutics upholds a patient-centered philosophy through its Expanded Access Policy, which aims to broaden patient access to experimental treatments. The company collaborates closely with patients, families, and advocacy organizations, maintaining ethical transparency and clinical integrity throughout its research process. ### **Corporate and Research Environment** Based in Cambridge, Massachusetts, Relay Therapeutics fosters an integrated culture uniting research, clinical development, and data science. By combining structural biology with AI-driven computational science, the company seeks to establish a new paradigm in the discovery and development of next-generation medicines. ## Academic Sources and References 1. Relay Therapeutics. “About.” LinkedIn. Accessed October 23, 2025. https://www.linkedin.com/company/relay-therapeutics-inc./.Relay Therapeutics. “Dynamo Platform.” Official Website. Accessed October 23, 2025. https://relaytx.com/dynamo-platform/.Relay Therapeutics. “Home.” Official Website. Accessed October 23, 2025. https://relaytx.com/.Relay Therapeutics. “Patients.” Official Website. Accessed October 23, 2025. https://relaytx.com/patients/.Relay Therapeutics. “Pipeline.” Official Website. Accessed October 23, 2025. https://relaytx.com/pipeline/.Relat Therapeutics. “Team.” Official Website. Accessed October 23, 2025. https://relaytx.com/our-team/Relay Therapeutics. “Who We Are.” Official Website. Accessed October 23, 2025. https://relaytx.com/who-we-are/.